ask why

Latest research

Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.

Regulatory news

EU · EU licence (European Commission)

Belantamab mafodotin (Blenrep)

Blenrep is indicated in adults for the treatment of relapsed or refractory multiple myeloma: in combination with bortezomib and dexamethasone in patients who have received at least one prior therapy; and in combination with pomalidomide and dexamethasone in patients who have received at least one prior therapy including lenalidomide.

CHMP opinion 22 May 2025 → EU licence 23 Jul 2025 · GlaxoSmithKline Trading Services Limited

Research

Oncology · Br J Cancer · 2026-04-13

Secondary exposure-response analysis of DREAMM-6 Arm B and DREAMM-7 in relapsed/refractory multiple myeloma: higher belantamab mafodotin exposure with BVd was linked to better response without more grade ≥3 ocular events, favouring 2.5 over 1.9 mg/kg.

RCT
Papathanasiou et al. Exposure-response analyses for belantamab mafodotin in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma from DREAMM-6 Arm B and DREAMM-7

Sign in to react

Enter your email and we send a 6-digit code and a link. No password.

Your name and role

These appear beside any methods concern you post and on your profile page.